Fusion Pharmaceuticals' reported Q2 cash and investments of $226.5M, which is a significant amount. This strong financial position is expected to fund the company's operations into Q2 of 2025, indicating financial stability and reducing the risk of cash flow problems in the near future. This is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.